Recent News

• 04.03.2025 - Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 04.03.2025 - Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 04.03.2025 - Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy
• 03.26.2025 - Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
• 03.26.2025 - Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
• 03.12.2025 - Jefferies Biotech on the Beach Summit
• 03.11.2025 - Barclays 27th Annual Global Healthcare Conference
• 03.10.2025 - Leerink 2025 Global Biopharma Conference
• 03.04.2025 - Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 03.04.2025 - Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.28.2025 - S-8 Securities to be offered to employees in employee benefit plans